{"analyses":[{"ciLowerLimit":"1.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"19.6","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0167","paramType":"Odds Ratio (OR)","paramValue":"5.2","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.9","upperLimit":"95.5","value":"84.0"},{"groupId":"OG001","lowerLimit":"29.9","upperLimit":"70.1","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with or without Pembrolizumab)","dispersionType":"95% Confidence Interval","groups":[{"description":"160 mg Selpercatinib administered orally BID continuously in 21-day cycles.","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg) IV or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"OG001","title":"Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)"}],"paramType":"NUMBER","populationDescription":"CNS Overall: All participants included in the ITT population who had baseline CNS assessment and who had CNS metastasis at baseline.","reportingStatus":"POSTED","timeFrame":"Baseline through CNS Progression or Death Up to 31 Months","title":"Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}